Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| vTv Therapeutics Inc.VTVT · Entity 6614 | Chief Financial Officer | February 27, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
vTv Therapeutics Inc.
Report date February 27, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2034-02-27 | Direct | 74,659 |
Reported balance
After 2024-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-27 · Grant · Acquired 62,159 · Balance 74,659 F1: The option vests in quarterly equal installments over the three year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in quarterly equal installments over the three year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2024 Filed Jun 13, 2024 16:38 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantEmployee stock option (right to buy) · Derivative | 62,159 | $11.81 Strike: $11.81 | $734,097.79 |
DisclosureSEC source: 0001641489-24-000039 · wk-form4_1718311099.xml · derivative · entry 1 Tuch Steven L. · CIK 0001957337 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,659 Underlying: Class A Common Stock · 62,159 shares Expires 2034-02-27 F1 · derivative.exercise_date: The option vests in quarterly equal installments over the three year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 17:02 UTC | vTv Therapeutics Inc. VTVT · Entity 6614 | GrantDirector stock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000950142-22-003352 · es220312566_4-tuch.xml · derivative · entry 1 Tuch Steven L. · CIK 0001957337 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2032-12-12 F1 · derivative.exercise_date: An option to purchase 166,666 shares vests on December 12, 2023, and the remaining option to purchase 333,334 shares vests in equal quarterly installments over the two-year period beginning on December 12, 2023, subject to continued employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.